Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Recommended Blood Pressure Targets for Diabetes Are Being Challenged

By University of Gothenburg | August 24, 2016

The Swedish National Board of Health and Welfare recently raised the recommended target blood pressure for patients with diabetes. This may lead to more patients suffering from stroke or heart attack, according to a new study from the Sahlgrenska Academy. The new study is the world’s largest on the subject and is based on data from the National Diabetes Register.

In February 2015, the Swedish National Board of Health and Welfare raised the recommended goal for systolic blood pressure (blood pressure when the heart is contracting) in their guidelines for diabetes care.

The target blood pressure was raised from the previous level of below 130 mm Hg to below 140 mm Hg. The recommended target is important for how intensive antihypertensive treatment should be in patients with diabetes.

Linear relationship

The background for the revised recommendation was research suggesting that not only high blood pressure values, but also values below 130 mm Hg could lead to increased morbidity from cardiovascular diseases.

The researchers behind the new study are questioning this. Their study shows a linear relationship between blood pressure and cardiovascular disease. The lower the blood pressure, the fewer cases of stroke and myocardial infarction, even at the lowest levels.

“We believe that the recommendation to accept higher blood pressure in patients with diabetes is incorrect. It may lead to more cases of stroke and myocardial infarction in this patient group,” said Staffan Björck, Associate Professor of Nephrology at Sahlgrenska Academy, University of Gothenburg and one of the researchers behind the study.

187,000 patients

The new study is based on data from the National Diabetes Register, the Patient Register and the Prescribed Drug Register. It covers 187,000 patients with type 2 diabetes, who were followed for an average of 5 years.

The main difference between this study and the studies on which the Swedish National Board of Health and Welfare based its recommendations is that patients who already suffered from serious diseases were not included in the new study.

“What we have seen in our study is that, if we exclude individuals with previous severe disease, then the connection between low blood pressure and increased risk of stroke and myocardial infarction disappears,” said Samuel Adamsson Eryd, MD, the primary author of the study.

There is a natural explanation for this.

“If patients with diseases that can cause low blood pressure are also included in a study, the overall interpretation might be that low blood pressure leads to more cardiovascular disease,” said Staffan Björck.

300,000 patients in Sweden

There are approximately 300,000 patients with diabetes in Sweden, but they are not the only ones affected by the revised blood pressure targets. Both European and American expert organizations have raised the recommended goal for systolic blood pressure to below 140 mm Hg. As the new study is much larger than all previous studies on the topic, it is important for discussions of blood pressure targets, both in Sweden and abroad.

The study Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study was published in BMJon August 4.


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50